{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:56:53Z","timestamp":1782845813349,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T00:00:00Z","timestamp":1569110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This analysis assessed migraine\u2010related burden and treatment decisions in Chronic Migraine Epidemiology and Outcomes (CaMEO) Study survey respondents who stopped taking acute prescription medications for migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a common yet underdiagnosed and undertreated neurological disease often associated with significant disability. Acute prescription medications are underused, in part because patients discontinue treatment. Rates and reasons for discontinuing acute prescription medications require exploration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The CaMEO Study is a longitudinal, Internet\u2010based survey that identified and followed people who met modified ICHD\u20103 migraine criteria. For this analysis, eligible respondents had used acute prescription medication for migraine in the past but no longer used or kept these treatments on hand (discontinued users). Respondents who reported discontinuing acute prescription treatment answered questions about length of time since last use and reasons for stopping. Reasons for discontinuing were thematically summarized. Monthly headache day frequency, Migraine Disability Assessment (MIDAS), Patient Health Questionnaire 9\u2010item depression screener, Generalized Anxiety Disorder 7\u2010item screener, and the 12\u2010item Allodynia Symptom Checklist were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 13,624 respondents with migraine, 4840 (35.5%) had ever used acute prescription medications and 1719 (35.5%) of those were discontinued users. Discontinued users had a mean (SD) age of 42.1 (14) years, and 1348\/1719 (78.4%) were female. Monthly headache frequency of 0\u20104\u00a0days was reported by 1073\/1719 (62.4%) of respondents, 5\u20109\u00a0days by 322\/1719 (18.7%), 10\u201014\u00a0days by 135\/1719 (7.9%), and \u226515\u00a0days by 189\/1719 (11.0%). Two\u2010thirds (1160\/1719 [67.5%]) of discontinued users reported a receiving migraine (or chronic migraine) diagnosis from a doctor or other health professional in the past. Although all had spoken to a doctor about their headaches, 1504\/1719 (87.5%) had stopped having their headaches managed or treated by a doctor for at least 12\u00a0months. Only 1 in 5 discontinued users reported being able to work or function normally with a headache, and 717\/1719 (41.7%) had moderate to severe disability (MIDAS). Among the most commonly reported reasons for prescription medication discontinuation were switching to non\u2010prescription pain medication (782\/1719 [45.5%]), as well as concerns about prescription medication efficacy (484\/1719 [28.2%]) and tolerability (428\/1719 [24.9%]). Nearly half of respondents who reported either efficacy or tolerability concerns had moderate to severe disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>People with migraine who discontinue acute prescription medication have a high level of unmet treatment need. The majority cannot work or function normally with headaches, with 646\/1719 (37.6%) of discontinued users reporting 5 or more headache days per month.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13642","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:39:55Z","timestamp":1569199195000},"page":"1762-1772","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study"],"prefix":"10.1111","volume":"59","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Orange County Migraine &amp; Headache Center Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Medstar Georgetown University Hospital Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Reed","sequence":"additional","affiliation":[{"name":"Vedanta Research Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Fanning","sequence":"additional","affiliation":[{"name":"Vedanta Research Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Manack Adams","sequence":"additional","affiliation":[{"name":"Allergan plc Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010917"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01819.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02050.x"},{"key":"e_1_2_9_7_1","volume-title":"Drug Safety Communication: FDA Strengthens Warning that Non\u2010Aspirin Nonsteroidal Anti\u2010Inflammatory Drugs (NSAIDs) Can Cause Heart Attacks or Strokes","author":"Food and Drug Administration","year":"2015"},{"key":"e_1_2_9_8_1","volume-title":"Imitrex [package insert]","year":"2017"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1026325"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828aab14"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12233"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"e_1_2_9_16_1","volume-title":"Does adding acute treatment improve migraine outcomes in patients on triptans?: Results of the America Migraine Prevalence & Prevention (AMPP) Study [abstract]","author":"Serrano D","year":"2012"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12201"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03027.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X46269"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410383058"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414552532"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0552-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21211"},{"issue":"15","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"S59.008","DOI":"10.1212\/WNL.92.15_supplement.S59.008","article-title":"Patterns and characterization of acute prescription migraine medication use: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study [abstract]","volume":"92","author":"Hutchinson S","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04124.x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01343.x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_9_34_1","first-page":"68","article-title":"Triptan use and discontinuation in a representative sample of persons with migraine: Results from Migraine in America Symptoms and Treatment (MAST) study [abstract OR11]","volume":"58","author":"Alam A","year":"2018","journal-title":"Headache"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:45:37Z","timestamp":1762083937000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,22]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/head.13642"],"URL":"https:\/\/doi.org\/10.1111\/head.13642","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,22]]},"assertion":[{"value":"2019-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}